XML 40 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
SEGMENT INFORMATION
9 Months Ended
Sep. 30, 2016
SEGMENT INFORMATION  
SEGMENT INFORMATION

17. SEGMENT INFORMATION

 

The Company operates in one reportable segment—the development and commercialization of novel therapeutic products. The Company has identified its Chief Executive Officer as the Chief Operating Decision Maker, or CODM, who manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating financial performance, the CODM reviews individual customer and product information, while other financial information is reviewed on a consolidated basis. Therefore, results of operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Disclosures about revenues by product and by geographic area are presented below.

 

Geographic Information

 

Outside the United States, or ROW, the Company sells avanafil (STENDRA/SPEDRA) through a commercialization licensee principally in the EU. The geographic classification of product sales was based on the location of the customer. The geographic classification of supply, license and milestone revenue was based on the domicile of the entity from which the revenue was earned.

 

Net product revenue by geographic region was as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30, 

 

 

 

2016

 

2015

 

 

 

U.S.

 

     ROW     

 

Total

 

U.S.

 

     ROW     

 

Total

 

Qsymia—Net product revenue

    

$

12,294

    

$

 —

    

$

12,294

    

$

14,011

    

$

 —

    

$

14,011

 

STENDRA/SPEDRA—License and milestone revenue

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

STENDRA/SPEDRA—Supply revenue

 

 

 —

 

 

 —

 

 

 —

 

 

5,020

 

 

5,036

 

 

10,056

 

STENDRA/SPEDRA —Royalty revenue

 

 

425

 

 

634

 

 

1,059

 

 

307

 

 

562

 

 

869

 

Total revenue

 

$

12,719

 

$

634

(1)  

$

13,353

 

$

19,338

 

$

5,598

(2)  

$

24,936

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30, 

 

 

 

2016

 

2015

 

 

 

U.S.

 

ROW

 

Total

 

U.S.

 

ROW

 

Total

 

Qsymia—Net product revenue

    

$

37,455

 

$

 —

 

$

37,455

 

$

40,652

 

$

 —

 

$

40,652

 

STENDRA/SPEDRA—License and milestone revenue

 

 

 —

 

 

 —

 

 

 —

 

 

 —

 

 

11,574

 

 

11,574

 

STENDRA/SPEDRA—Supply revenue

 

 

 —

 

 

1,526

 

 

1,526

 

 

16,602

 

 

10,049

 

 

26,651

 

STENDRA/SPEDRA —Royalty revenue

 

 

1,649

 

 

1,823

 

 

3,472

 

 

(348)

 

 

1,558

 

 

1,210

 

Total revenue

 

$

39,104

 

$

3,349

(3)  

$

42,453

 

$

56,906

 

$

23,181

(4)  

$

80,087

 

 


(1)

$0.6 million of which was attributable to Germany.

(2)

$5.6 million of which was attributable to Germany.

(3)

$3.3 million of which was attributable to Germany.

(4)

$23.1 million of which was attributable to Germany.